Agenus (AGEN)
(Delayed Data from NSDQ)
$5.09 USD
-0.19 (-3.60%)
Updated Aug 9, 2024 04:00 PM ET
Pre-Market: $5.10 +0.01 (0.20%) 8:30 AM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Brokerage Reports
Agenus Inc. [AGEN]
Reports for Purchase
Showing records 241 - 260 ( 260 total )
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2010 RECAP & 2011 PREVIEW
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Expansion of Phase 2 Trial in Newly-Diagnosed Glioma with a View to Phase 3 Development
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2Q10 UPDATE - AG707 DEMONSTRATES UNPRECEDENTED IMMUNE RESPONSES
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Trial of AG-707 Showcases Unprecedented Responses Against Genital Herpes
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Oncophage Demonstrates Substantial Survival Advantage in Recurrent Glioma
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Oncophage Demonstrates Substantial Survival Advantage in Recurrent Glioma
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q10 UPDATE - EU REGULATORS CONSULTED ON PATH FOR ONCOPHAGE
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R